lorazepam has been researched along with gemfibrozil in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T | 1 |
He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Deguchi, T; Furuta, Y; Fusegawa, K; Hirouchi, M; Igeta, K; Ikenaga, H; Iwasaki, M; Izumi, T; Kurihara, A; Murata, S; Okazaki, O; Suzuki, N; Watanabe, N | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Konishi, K; Minematsu, T; Nagasaka, Y; Tabata, K | 1 |
1 review(s) available for lorazepam and gemfibrozil
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for lorazepam and gemfibrozil
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
Topics: Anilino Naphthalenesulfonates; Animals; Fatty Acid-Binding Proteins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Fluorescence; Substrate Specificity | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Area Under Curve; Cytochrome P-450 Enzyme System; Dogs; Drug Evaluation, Preclinical; Glucuronides; Glucuronosyltransferase; Half-Life; Humans; Macaca fascicularis; Male; Mice; Pharmaceutical Preparations; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Species Specificity | 2011 |
Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aging; Butyrylcholinesterase; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Desipramine; Drug Interactions; Female; Gemfibrozil; Glucuronosyltransferase; Humans; Itraconazole; Lorazepam; Male; Middle Aged; Models, Biological; Renal Insufficiency; Thiazoles; Young Adult; Zidovudine | 2019 |